Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Venturi Wealth Management LLC

Venturi Wealth Management LLC grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 61.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,616 shares of the medical research company’s stock after acquiring an additional 614 shares during the quarter. Venturi Wealth Management LLC’s holdings in Charles River Laboratories International were worth $318,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CRL. Covestor Ltd boosted its stake in Charles River Laboratories International by 40.9% during the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 95 shares during the period. Assetmark Inc. boosted its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the period. Principal Financial Group Inc. grew its holdings in Charles River Laboratories International by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company’s stock worth $11,917,000 after buying an additional 2,126 shares in the last quarter. Ground Swell Capital LLC acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at approximately $283,000. Finally, Cambiar Investors LLC raised its stake in Charles River Laboratories International by 1.1% during the 3rd quarter. Cambiar Investors LLC now owns 45,930 shares of the medical research company’s stock valued at $9,047,000 after acquiring an additional 494 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CRL shares. Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Bank of America lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. cut Charles River Laboratories International from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Finally, TD Cowen increased their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $217.54.

Charles River Laboratories International Stock Down 2.2 %

CRL stock opened at $215.84 on Wednesday. The company’s 50 day simple moving average is $194.85 and its 200-day simple moving average is $207.91. Charles River Laboratories International, Inc. has a 52-week low of $168.24 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.21. The firm has a market capitalization of $11.04 billion, a P/E ratio of 27.01, a P/E/G ratio of 5.80 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the company earned $2.72 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.2 EPS for the current year.

Charles River Laboratories International announced that its board has authorized a share buyback program on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).